ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.32
-1.10%
US Tech 100
21,189.20
-1.40%
S&P 500
6,034.35
-1.36%
US Dollar vs CAD
1.42231
0.34%
Bitcoin
96,909.71
-1.43%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lantern Pharma Inc (LTRN) Share Price

Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

NASDAQ
4.4201
0.0901
( 2.08% )
Updated: 12:07:45
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.4201
Bid
4.36
Ask
4.47
Volume
51,548
4.25 Day's Range 4.60
2.79 52 Week Range 11.99
Market Cap
47.67M
Previous Close
4.33
Open
4.37
Last Trade
20
@
4.45
Last Trade Time
12:13:42
Financial Volume
US$ 224,159
VWAP
4.3485
Average Volume (3m)
109,239
Shares Outstanding
10,784,725
Dividend Yield
-
PE Ratio
-2.99
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-15.96M

About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was US$4.33. Over the last year, Lantern Pharma shares have traded in a share price range of US$ 2.79 to US$ 11.99.

Lantern Pharma currently has 10,784,725 shares outstanding. The market capitalization of Lantern Pharma is US$46.70 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.99.

Ask ADVFN Intelligence (AI)

LTRN Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
January 10 2025
LTRN (2.08%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 07 2024
LTRN (2.08%)

Form 8-K - Current report
Edgar (US Regulatory)
November 07 2024
LTRN (2.08%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3799-7.914583333334.85.064.152750814.60456037CS
40.19014.494089834524.236.1184.151743705.05928505CS
121.280140.76751592363.146.1182.951092394.4570716CS
26-0.0799-1.775555555564.56.1182.79744064.14075055CS
520.430110.77944862163.9911.992.791400746.15008574CS
156-2.1099-32.31087289436.5311.992.38704965.73437976CS
260-10.7399-70.843667546215.1624.842.38766659.25187514CS

LTRN - Frequently Asked Questions (FAQ)

What is the current Lantern Pharma share price?
The current share price of Lantern Pharma is US$ 4.4201
How many Lantern Pharma shares are in issue?
Lantern Pharma has 10,784,725 shares in issue
What is the market cap of Lantern Pharma?
The market capitalisation of Lantern Pharma is USD 46.7M
What is the 1 year trading range for Lantern Pharma share price?
Lantern Pharma has traded in the range of US$ 2.79 to US$ 11.99 during the past year
What is the PE ratio of Lantern Pharma?
The price to earnings ratio of Lantern Pharma is -2.99
What is the reporting currency for Lantern Pharma?
Lantern Pharma reports financial results in USD
What is the latest annual profit for Lantern Pharma?
The latest annual profit of Lantern Pharma is USD -15.96M
What is the registered address of Lantern Pharma?
The registered address for Lantern Pharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
Which industry sector does Lantern Pharma operate in?
Lantern Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
US$ 7.6492
(565.15%)
395.76M
IVVDInvivyd Inc
US$ 1.8593
(53.66%)
22.89M
GDEVGDEV Inc
US$ 20.305
(42.39%)
205.46k
TXMDTherapeuticsMD Inc
US$ 1.38
(36.63%)
12.01M
UPCUniverse Pharmaceuticals Inc
US$ 0.1925
(35.09%)
366.39M
DOYUDouYu International Holdings Ltd
US$ 7.23
(-55.07%)
1.05M
MNDRMobile health Network Solutions
US$ 0.5312
(-43.48%)
15.68M
BLUEbluebird bio Inc
US$ 4.1892
(-40.49%)
4.45M
FLDFold Holdings Inc
US$ 7.531
(-32.15%)
284.01k
AXTIAXT Inc
US$ 1.5701
(-31.44%)
5.09M
MLGOMicroAlgo Inc
US$ 7.62
(562.61%)
395.77M
UPCUniverse Pharmaceuticals Inc
US$ 0.1906
(33.75%)
366.41M
ADTXAditxt Inc
US$ 0.0966
(-18.69%)
212.22M
HOLOMicroCloud Hologram Inc
US$ 1.4601
(22.70%)
144.93M
NVDANVIDIA Corporation
US$ 136.97
(-2.24%)
111.44M

LTRN Discussion

View Posts
Monksdream Monksdream 6 months ago
LTRN under $5
👍️0
anabu9 anabu9 6 months ago
Finally an UP day. 'hope institutions will see this nugget soon
👍️0
FALCON1 FALCON1 7 months ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
dinogreeves dinogreeves 10 months ago
Nice drop
🕳️ 1 🪦 1 ⚰️ 1
Monksdream Monksdream 10 months ago
LTRN under $10
👍️0
Monksdream Monksdream 11 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
dinogreeves dinogreeves 11 months ago
Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.
👍️0
dinogreeves dinogreeves 11 months ago
I think we can revisit the high again hopefully this week. Been here since 7.20
🖕🏻 1
spartex spartex 11 months ago
10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023
👍️0
Monksdream Monksdream 11 months ago
LTRN new 52 hi
👍️0
dinogreeves dinogreeves 11 months ago
Another very good day today.
👍️0
Monksdream Monksdream 11 months ago
LTRN 10Q due 3/18
👍️0
dinogreeves dinogreeves 11 months ago
Very good move on Friday.
🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
dinogreeves dinogreeves 11 months ago
This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.
👍️0
dinogreeves dinogreeves 11 months ago
This is going to have one heck of a run.
👍️0
Tremors! Tremors! 11 months ago
Will they break 10.00!??
👍️0
Roily23 Roily23 12 months ago
👍️0
Roily23 Roily23 12 months ago
AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
👍️0

Your Recent History

NASDAQ
LTRN
Lantern Pharma
CSE
BTC
Bluesky Digital Assets
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads